OPTN logo

OptiNose, Inc. Common Stock


OPTN: OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.


Show OPTN Financials

Consumer Interest
SEC Filings

Recent trades of OPTN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by OPTN's directors and management

Government lobbying spending instances

  • $10,000 Jul 20, 2021 Issue: Health Issues Budget/Appropriations
  • $30,000 Apr 19, 2021 Issue: Health Issues Budget/Appropriations
  • $20,000 Jan 19, 2021 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Intranasal administration Aug. 22, 2023
  • Patent Title: Intranasal administration Jul. 25, 2023
  • Patent Title: Delivery of gases to the nasal airway Jul. 04, 2023
  • Patent Title: Nasal delivery devices Mar. 14, 2023
  • Patent Title: Powder delivery devices Feb. 07, 2023
  • Patent Title: Nasal administration Jan. 17, 2023
Government Contracts

Federal grants, loans, and purchases


Number of mentions of OPTN in WallStreetBets Daily Discussion


Recent insights relating to OPTN

CNBC Recommendations

Recent picks made for OPTN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OPTN

Corporate Flights

Flights by private jets registered to OPTN